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Summary objectives To provide more accurate estimates of the prevalence of Hepatitis B (HBV) and
Hepatitis C (HCV) and their contributing factors among prisoners in Iran.
methods Cross-sectional study of 6200 Iranian prisoners in 2015. Data were collected through
questionnaires and interviews. HBV infection and HCV exposure status of the participants was
determined by HBsAg and HCV antibodies blood tests using enzyme-linked immunosorbent assay
(ELISA). Data were analysed in STATA-12.
result Prevalence of HCV exposure was 9.48% (95% CI: 8.73–10.27), and prevalence of HBV was
2.48% (95% CI: 2.07–2.89) in the general prison population. In multivariate analysis, the most
important risk factor for HBV was a history of drug use in lifetime (adjusted odds ratio, AOR: 1.8,
95% CI: 1.17–3.02). The main risk factors for HCV exposure were a history of drug use in lifetime
(AOR: 4.08, CI: 2.56–6.27), age over 30 (AOR: 2.68, CI: 2.01–3.56), and having tattoos
(AOR = 1.67, CI: 1.35–2.07).
conclusion Although vaccination is used to control HBV among prisoners, prevalence of HCV
exposure is alarming in the prison population of Iran, especially among people who inject drugs.
Eliminating viral hepatitis in Iran by 2030 requires a national commitment and rapid measures for
targeting this high-risk group. Given the increased efficiency of HCV treatment in recent years,
prisons provide an opportunity to access patients for treatment.
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Introduction
Viral hepatitis is one of the most important causes of
mortality and disability worldwide, but unlike most
other infectious diseases, its absolute burden and relative
rank have increased from 1990 to 2013. This major
human health challenge has been neglected until
recently; it is now viewed as a major global health chal-
lenge. Hepatitis B (HBV) and Hepatitis C (HCV) are the
most important types of viral hepatitis causing this high
burden [1]. Although an initially neglected disease, the
fight against hepatitis is now among sustainable develop-
ment goals (SDGs), and its control has become an SDG
index for 2030 [2]. About 815 000 and 488 000 deaths
from HBV and HCV are globally reported every year
[3].
Public vaccination against HBV has been carried out
since 1994 for newborns in Iran. According to a system-
atic review, the prevalence of HBV has fallen over the
past decades and was estimated at 1.79% in the general
population [4]; the prevalence of HCV has been esti-
mated as 0.4% [5]. Despite the low prevalence of HCV
in the general population of Iran, a large outbreak of
HCV has been reported among high-risk groups in Iran,
with a prevalence of approximately 45% among people
who inject drugs (PWID) [6].
Prisoners are a high-risk group for Blood Borne Dis-
eases (BBD). In many countries, the prevalence of
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hepatitis and HIV is reportedly several times higher in
prisoners than in the general population. The global
prevalence of HCV among prisoners is estimated to range
from 3.1% to 38%. A higher prevalence of HCV has
been reported in Asian countries [7]. Prisoners are at a
high risk of contracting these diseases as prisons are a
host to groups of people with high-risk behaviours. In
most parts of the world, the structure of prisons makes it
difficult to implement preventive programmes against the
transmission and spread of BBD; as a result, prisons are
considered high-risk environments and prisoners a high-
risk group for the transmission and spread of BBDs [8,
9]. High prevalence of drug use is one of the risk factors
for developing BBDs. 10–60% of prisoners around the
world have a history of drug use, and drug use is thus
correlated with viral hepatitis [10].
The WHO has set the new target of eliminating HCV
by 2030 and recommends that all countries design and
implement HBV control and HCV elimination pro-
grammes. Also, indices for monitoring the progress of
disease control have been introduced [11]. Despite the
disparate studies on the prevalence of HBV and HCV in
Iranian prisons, most studies have been conducted in cer-
tain subgroups at the local level with limited sample sizes
and different constraints, and their results cannot be gen-
eralised to the national level.
Iran is currently developing a national strategic plan to
control and reduce the burden of viral hepatitis in line
with the Sustainable Development Goals (SDGs). Owing
to the access to treatment and its increased success,
reducing HCV to >90% of the total cases by 2030
requires the adoption of key strategies such as the identi-
fication of high-risk groups and the implementation of
the required interventions [12]. Precise estimates of the
prevalence and risk factors for HCV in high-risk groups
and specific subgroups are a prerequisite of achieving this
goal. Given that prisoners are a high-risk group for BBD,
and considering the need for making an accurate estimate
of the status and prevalence of HBV and HCV exposure
among Iranian prisoners and their risk factors, this study
was conducted to determine estimates of the prevalence
of HBV and HCV exposure among prisoners in Iran and
their risk factors.
Methods
This cross-sectional study was the first HBV and HCV
bio-behavioural surveillance survey in Iran, conducted in
2015. The statistical population consisted of all the pris-
oners of Iran who were selected through multistage sam-
pling. For this purpose, the country was divided into
three geographical regions, that is the north, centre and
south, and each region was considered as a stratum from
which three provinces were then randomly selected. Nine
of the 31 provinces of Iran were thus included in the
research as clusters. In the next stage, two or three pris-
ons (a total of 26 prison sites) were selected from each
cluster using probability proportional-to-size sampling
(i.e. according to the number of prisoners in each clus-
ter). Samples were then randomly selected from the cho-
sen prisons from the lists of prisoners.
Taking into account an overall prevalence rate of 9%
for hepatitis C, a confidence interval of 95% and a rela-
tive error of 10% for the estimated prevalence, the sam-





Þ2p 1 pð Þ ¼ ð 1:96
0:009
Þ2  0:09  0:91 ¼ 3884
d ¼ 0:1  0:09 ¼ 0:009
The 31 provinces were then divided into three geograph-
ical regions including the north, centre and south. For each
stratum, three clusters (provinces) were selected and
included in the study. In the next step, taking into account
a design effect of 1.4, the sample size was calculated as
5437 people. Finally, considering a non-response rate of
15%, the final sample size was estimated as 6200 people.
Interviewers were trained on how to collect the data
and interview the participants. Data collection was by a
questionnaire which inquired about participants’ demo-
graphic data, history of high-risk behaviours such as drug
use in lifetime, and unsafe sex in lifetime. Unsafe sex was
defined as a history of having an extramarital affair dur-
ing the lifetime or having sex in prison as a dichotomous
variable (has/does not have). The validity and reliability
of the questionnaire used in this study for measuring
high-risk behaviours had been investigated [13]. With
consent from the participants, data were collected
through interviews and questionnaires. Blood samples
were taken from the participants for testing by dried
blood spots, stored in standard conditions and tested in
the laboratory of the Pasteur Institute of Iran to reduce
the risk of bias.
HBsAg and HCV antibodies (HCV Ab) were detected
using the enzyme-linked immunosorbent assay (ELISA)
and Dia Pro kits (Diagnostic Bioprobes Srl, Italy). The
validity of the test was ensured by using calibrators and
positive and negative controls supplied by the manufac-
turer according to the protocol provided in the manual.
Positive and negative samples were determined based on
optical density (OD) and cut-off points.
The research proposal was approved by the Ethics
Committee of Kurdistan University of Medical Sciences
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in terms of technical and ethical codes. Written consent
was given by all willing participants; those who refused
were excluded from the study and sampling.
Data were analysed using descriptive and analytical
statistics. The relationship between the risk factors and
the prevalence of HBV and HCV exposure was assessed
by calculating the Odds Ratio (OR) using univariate
logistic regression. When reaching a P-value <0.2 in the
univariate logistic, the variables were entered into the
adjusted logistic model and their adjusted odds ratio
(AOR) was calculated. All analyses were performed in
STATA-12.
Results
A total of 5508 of the 6200 samples selected participated
in the study (response rate = 88.8%). The mean age of
participants was 39.49  12.74 years. A total of 5314
(96.5%) participants were men, 2935 (53%) were mar-
ried, and 2968 (55.3%) had a history of previous impris-
onment. 74% had a history of drug use in their lifetime,
17% had injected drugs, 43% had tattoos, and 54% had
a history of unsafe sex.
Table 1 presents the prevalences by variables. HCV
exposure showed a prevalence of 9.48% (95% CI: 8.73–
10.27) in the general prison population. The prevalence
of HCV exposure was 12.87% (95% CI: 11.68–14.12),
12.11% (95% CI: 11.12–13.15), 42.47% (95% CI:
38.78–46.29) and 13.46% (95% CI: 12.11–14.90),
respectively, among the prisoners with a history of
imprisonment, drug use, injected drug use, and tattoos.
The prevalence of HBV was 2.48% (95% CI: 2.07–
2.89) in the general prison population and varied in the
prisons by age group (P = 0.009): it was 3.11% (95%
CI: 2.35–4.02) in the 30 to 40-year age group and
3.24% (95% CI: 2.19–4.59) in the 40- to 50-year age
group. HBV prevalence was 2.84% (95% CI: 2.35–3.40)
in participants with a history of drug use and 4.41%
(95% CI: 2.03–8.20) in those with a history of sexually
transmitted infections (STI) in the previous year
(Table 1).
Tables 2–4 present the results of logistic regression
analysis. In Table 2, which includes the general popula-
tion of prisoners, age >30 (AOR = 2.68, 95% CI: 2.01–
3.56), being single (AOR = 1.77, CI: 1.42–2.22), history
of previous imprisonment (AOR = 1.75, CI: 1.38–2.21),
a history of drug use (AOR = 4.08, CI: 2.65–6.27) and
having tattoos (AOR = 1.67, CI: 1.35–2.07) were all
identified as significant risk factors for HCV exposure.
However, a history of drug use (AOR = 1.88, CI: 1.17–
3.02) was the only significant risk factor for HBV in the
general population of prisoners (Table 2).
In prisoners with a history of drug use, age >30 years
(AOR = 1.73, CI: 1.19–2.52), injected drug use
(AOR = 11.03, CI: 8.19–14.85), and an absence of his-
tory of methadone maintenance therapy (MMT)
(AOR = 1.39, CI: 1.04–1.86) were predisposing factors
for HCV exposure. Moreover, age >30 years
(AOR = 1.74, CI: 1.06–2.87) was a significant risk factor
for HBV (Table 3).
In PWID prisoners, a history of unsafe sex was a pre-
disposing factor for HCV exposure (AOR = 1.59, CI:
1.1–2.3) and a history of needle-sharing (AOR = 3.36,
CI: 1.25–9.02) was a predisposing factor for HBV
(Table 4).
Discussion
The prevalence of HCV exposure was approximately
10% in the general prison population and nearly 43% in
PWID prisoners. Given that the prevalence of HCV is
0.4% in the general population [14], these values are 25
and 100 times higher in prisons than the general popula-
tion. In France, the prevalence of HCV was estimated to
be six times higher in the general prison population than
in the general population [15].
The undesirable health conditions among prisoners are
attributed to high-risk behaviours such as drug use (e.g.
PWID), unsafe sex, tattoos and violence [16, 17]. The
burden of HCV has been growing in Iran since 1990,
and the main high-risk groups of this disease have been
PWID and prisoners [18]. Given that the prevalence of
HCV is reported as 1–15% in prisons across the world
[19–21], Iran is a country with a relatively high preva-
lence. This high prevalence seems to be due to the large
number of PWID prisoners, which demonstrates the need
for the adoption of more effective strategies and the
reconsideration of the existing plans for HCV control.
The spread of HCV is similar to the HIV epidemic in
Iran, which occurred more than a decade ago and in
which prisons played an important role. The epidemic
was controlled by implementing harm reduction pro-
grammes in prisons. MMT is one of the main harm
reduction activities in Iranian prisons, as more than
30 000 prisoners in the 164 prisons have access to this
service. Another important harm reduction activity for
controlling HIV/AIDS are Triangular Clinics, which oper-
ate in approximately 128 prisons from 31 provinces of
Iran [22].
Having a history of drug use in the general population
of prisoners and injecting drug use in the drug-using pris-
oners were the risk factors for HCV exposure. This find-
ing is in line with the prevailing pattern in other prisons
in the world [7, 23, 24]. Moreover, tattoos were a risk
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Table 1 The prevalence of HBV & HCV in Iranian prisoners based on various variable
Variable Sample size
HCV HBV
Positive Prevalence(CI) P-value* Positive Prevalence(CI) P-value
Country region
North 1728 127 7.34 (6.16–8.68) 0.000 40 2.31 (1.65–3.13) 0.015
Centre 2198 262 11.91 (10.59–13.34) 43 1.95 (1.42–2.62)
South 1582 133 8.40 (7.08–9.88) 54 3.41 (2.57–4.03)
Total 5508 522 9.47 (8.7–10.2) 137 2.48 (2.07–2.89)
Sex
Male 5314 511 9.61 (8.83–10.44) 0.06 130 2.44 (2.04–2.89) 0.3
Female 194 11 5.67 (2.89–9.91) 7 3.60 (1.46–7.29)
Age group
≤30 1558 79 5.07 (4.03–6.27) 0.001 28 1.79 (1.19–2.58) 0.009
31–40 1799 194 10.7 (9.38–12.3) 56 3.11 (2.35–4.02)
41–50 925 128 13.8 (11.7–16.2) 30 3.24 (2.19–4.59)
51–60 775 84 10.8 (8.84–13.2) 19 2.45 (1.57–3.79)
>60 449 37 8.24 (6.03–11.10) 4 0.89 (0.34–2.26)
Education
Illiterate 510 42 8.23 (5.84–10.61) 0.004 16 3.13 (1.94–5.03) 0.11
Primary 1532 161 10.50 (9.02–12.1) 30 1.95 (1.37–2.78)
Secondary 1802 193 10.71 (9.31–12.23) 53 2.94 (2.25–3.82)
High Scholl 1330 107 8.04 (6.63–9.63) 26 1.95 (1.33–2.84)
University degree 331 18 5.43 (3.46–8.43) 12 3.62 (2.08–6.22)
Marriage status
Married 2935 223 7.59 (6.66–8.61) 0.000 81 2.75 (2.19–3.41) 0.18
Single 2573 299 11.62 (10.40–12.92) 56 2.17 (2.81–2.73)
Duration of current imprisonment
0–1 1597 133 8.32 (7.01–9.73) 0.364 40 2.50 (1.70–3.39) 0.508
1–2 1313 127 9.67 (8.12–11.4) 29 2.20 (1.43–3.15)
2–3 739 72 9.74 (7.70–12.11) 20 2.70 (1.66–4.14)
3–4 405 37 9.13 (6.51–12.37) 15 4.94 (3.04–7.52)
>4 1451 152 10.47 (8.94–12.37) 33 2.27 (1.57–3.17)
History of previous imprisonment
Yes 2968 382 12.87 (11.68–14.12) 0.000 77 2.59 (2.05–3.23) 0.3
No 2461 125 5.07 (4.24–6.02) 60 2.43 (1.86–3.12)
No Response 79 15 18.98 (11.03–29.38) 0 0 (0–4.56)
History of drug use in lifetime
Yes 4078 494 12.11 (11.12–13.15) 0.000 116 2.84 (2.35–3.40) 0.01
No 1406 26 1.84 (1.21–2.69) 21 1.49 (0.92–2.27)
No Response 24 2 8.33 (1.02–26.99) 0 0 (0–14.24)
People who inject drug (PWID) in lifetime†
Yes 678 288 42.47 (38.72–46.29) 0.000 17 2.50 (1.46–3.98) 0.6
No 3400 194 5.7 (4.94–6.53) 95 2.79 (2.26–3.4)
History of needle-sharing in lifetime†
Yes 199 84 42.21 (35.26–49.39) 0.6 10 5.02 (2.43–9.04) 0.008
No 461 201 43.60 (39.01–48.26) 7 1.52 (0.61–3.10)
No Response 18 2 11.11 (1.37–34.71) 0 0 (0–18.53)
History of methadone maintenance therapy (MMT)
Yes 3001 180 5.99 (5.17–6.9) 0.000 79 2.63 (2.08–3.27) 0.9
No 1076 181 16.8 (14.61–19.17) 28 2.59 (1.73–3.73)
History of tattooing in lifetime
Yes 2362 318 13.46 (12.11–14.90) 0.000 60 2.54 (1.94–3.25) 0.9
No 3097 202 6.52 (5.68–7.45) 76 2.45 (1.93–3.06)
No Response 49 2 4.08 (0.49–13.97) 1 2.04 (0.05–10.85)
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factor for HCV exposure (AOR: 1.67) in the general pop-
ulation of prisoners. In line with our results, recent stud-
ies have shown a relationship between tattooing and
hepatitis C transmission [25, 26]. The other risk factors
in prisons with history of drug use include older age and
an absence of history of MMT. Older age is a risk factor
because it might imply a longer history of addiction. An
absence of history of MMT also implies more
commitment of high-risk behaviours such as injecting
drug use. The results of some studies have shown that
MMT reduces HCV seroconversion [27, 28]. When the
HIV/AIDS epidemic became apparent more than a decade
ago, which had become prevalent among injecting drug
users and in densely populated places such as prisons,
harm reduction programmes such as MMT became a pri-




Positive Prevalence(CI) P-value* Positive Prevalence(CI) P-value
History of unsafe sex in lifetime
Yes 2536 269 10.61 (9.43–11.87) 0.012 60 2.37 (1.81–3.03) 0.551
No 2122 179 8.44 (7.28–9.70) 56 2.64 (1.99–3.41)
History of sexually transmitted infections (STI) in last year
Yes 204 19 9.31 (5.70–14.16) 0.9 9 4.41 (2.03–8.20) 0.08
No 5304 503 9.48 (8.7–10.3) 128 2.41 (2.01–2.86)
*Result from Chi-Square test.
†‘PWID in lifetime’ question has been asked only of those said ‘yes’ to ‘history of drug use in lifetime’.
‡‘History of sharing injection in lifetime’ question has been asked only of those said ‘yes’ to ‘PWID’.
Table 2 Result from Logistic regression models for HCV & HBV in general population of prisons (N = 5508)
Variables
HCV HBV
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Gender
Female 1 1 1
Male 1.76 (0.95–3.27) 0.67 (0.31–1.45) 0.59 (0.27–1.29)
Age groups (years)
≤30 1 1 1
> 30 2.36 (1.85–3.02) 2.68 (2.01–3.56) 1.55 (1.02–2.36) 1.47 (0.96–2.24)
Educational level
Academic 1 1 1
Less than Diploma 1.84 (1.12–3) 0.95 (0.57–1.6) 0.64 (0.35–1.16)
Illiterate 1.91 (1.17–3.1) 1.01 (0.6–1.7) 0.86 (0.4–1.84)
Marital status
Married 1 1 1
Single 1.59 (1.35–1.94) 1.77 (1.42–2.22) 0.78 (0.55–1.11)
History of previous imprisonment
No 1 1 1
Yes 2.76 (2.23–3.4) 1.75 (1.38–2.21) 1.06 (0.75–1.5)
History of drug use in lifetime
No 1 1 1 1
Yes 7.31 (4.90–10.90) 4.08 (2.65–6.27) 1.93 (1.21–3.08) 1.88 (1.17–3.02)
History of unsafe sex in lifetime
No 1 1 1
Yes 1.28 (1.05–1.57) 1.01 (0.8–1.26) 0.89 (0.62–1.3)
History of tattooing in lifetime
No 1 1 1
Yes 2.22 (1.84–2.67) 1.67 (1.35–2.07) 1.02 (0.72–1.44)
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MMT programme has a wide coverage in the community
and in the prison, and is available to most injecting drug
users [22].
The estimates of the prevalence of HCV exposure in
the general prison population of Iran obtained in the pre-
sent study are consistent with the estimates provided by
Ziaee et al. [29] and Azarkar et al. [30] in Iran, who
reported HCV exposure prevalences of 7.7% and 7.8%.
Studies in the United States have estimated the prevalence
of this disease among prisoners as 10% [31]. The esti-
mates provided in some studies differ significantly from
ours. Amiri et al. and Heijnen et al. reported the HCV
prevalence among incarcerated populations in Iran as
34.7% and 37.8% [19, 32]. Our results provide more
accurate estimates and more up-to-date information for
policy makers owing to the large sample size, nationwide
coverage, design and bias control.
The prevalence of HBV in the general prison popula-
tion of Iran was 2.48%, which is almost double the esti-
mated prevalence in the general population, that is 1.3%
[33]. This reported prevalence is similar to the prevalence
reported among 1431 prisoners in three regions of Iran,
that is 3% [34]. A study in Spain reported an HBV
prevalence of 2.6% among prisoners [35]. Azarkar et al.
and Ziaee et al. reported these prevalences as 5.8% [30]
and 6.9% [29] in prisons in one of the provinces of Iran,
which are very different from the rates reported in the
present study. Perhaps these differences might be due to
the different methods as the sample sizes in the other two
studies are smaller than ours and the studies were con-
ducted in only one province.
We found that a history of drug use in lifetime among
prisoners is a risk factor for HBV (AOR: 1.88). Ziaee
et al. [29] also documented a high rate of HBV (9.3 vs.
2.6%, P < 0.001) in drug-using prisoners. Allwright et al.
[36] reported the risk of HBV in PWID as 21.16. Among
drug-using prisoners, age >30 years was a risk factor for
HBV, which is apparently due to HBV vaccination cover-
age for people <30 years in Iran [37, 38]. Prisoners, espe-
cially those with a history of drug use, should therefore
Table 3 Result from Logistic regression models for HCV & HBV in prison with a history of drug use (N = 4078)
Variables
HCV HBV
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Gender
Female 1 1
Male 1.43 (0.74–2.76) 0.5 (0.21–1.18)
Age groups (years)
≤30 1 1 1 1
>30 1.99 (1.54–2.57) 1.73 (1.19–2.52) 1.74 (1.06–2.87) 1.74 (1.06–2.87)
Educational level
Academic 1 1
Less than Diploma 1.3 (0.78–2.18) 0.55 (0.27–1.13)
Illiterate 1.3 (0.77–2.2) 0.48 (0.22–1.01)
Marital status
Married 1 1 1
Single 1.67 (1.38–2.02) 1.14 (0.84–1.55) 0.86 (0.59–1.25)
History of previous imprisonment
No 1 1 1
Yes 2.29 (1.82–2.87) 1.32 (0.95–1.83) 0.98 (0.67–1.44)
People who inject drug (PWID) in lifetime
No 1 1 1
Yes 11.65 (9.45–14.37) 11.03 (8.19–14.85) 0.85 (0.50–1.43)
History of unsafe Sex in lifetime
No 1 1 1
Yes 1.23 (1–1.52) 1.17 (0.8–1. 6) 0.9 (0.6–1.35)
History of tattooing in lifetime
No 1 1 1
Yes 1.86 (1.53–2.26) 1.12 (0.84–1.51) 0.78 (0.53–1.13)
History of methadone maintenance therapy (MMT)
Yes 1 1 1
No 2.26 (1.8–2.84) 1.39 (1.04–1.86) 0.81 (0.52–1.28)
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be treated as a high-risk group in Iran that needs to be
covered by HBV vaccination programmes.
History of unsafe sex in lifetime was a significant risk
factor for HCV exposure among PWID prisoners. Some
studies have reported multiple sex partners and unpro-
tected sex as risk factors for HCV transmission [39, 40].
Others have reported that the relationship between sexual
activity and HCV transmission as unknown [34, 41].
A history of needle-sharing in lifetime among PWID
prisoners was a risk factors for HBV. Ramezani et al.
[42] reported needle-sharing as a risk factor for HBV
transmission. The HBV epidemic in Iran has a relatively
long history in high-risk groups including prisoners.
Therefore, it is likely that HBV transmission through nee-
dle-sharing was related to the time when prisoners had
no access to harm reduction services.
An important finding of this study is that history of
needle-sharing in the lifetime is not a significant predictor
of HCV exposure in PWID prisoners, in contrast to the
findings of other studies [43, 44]. The reasons for this
probably include under-reporting of needle-sharing, high
coverage of MMT and needle and syringe programmes
(NSP). The HCV epidemic in Iran has been growing in
high-risk groups in recent years. Access to harm reduc-
tion services such as distribution of syringes and MMT
has increased in prisons and the community in recent
years, and may have decreased needle-sharing, whereas
the use of non-sterile equipment may have increased the
incidence of HCV in people using drugs.
Our study had limitations such as self-reporting and
recall bias. The data on history of unsafe sex and drug
use were obtained through self-reporting, which might
have been under-reported due to cultural conditions and
imprisonment. Moreover, in many cases, histories cov-
ered the prisoners’ lifetime, and they may not have cor-
rectly remembered events. Furthermore, because of
limited financial and logistical capabilities, HCV-RNA
could not be measured, although it is the most suitable
method for measuring the prevalence of HCV outbreaks.
Conclusion
In Iran, the prevalence of HCV exposure is 25 and 100
times higher among prisoners and PWID prisoners than
Table 4 Result from Logistic regression models for HCV & HBV in people who inject drug (PWID) in life-time (N = 678)
Variables
HCV HBV
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Gender
Female 1 1
Male 1.48 (0.44–4.98) 0.27 (0.03–2.22)
Age groups(Years)
≤30 1 1 1
> 30 1.45 (0.97–2.17) 1.439 (0.91–2.23) 1.08 (0.3–3.84)
Educational level
Academic 1 1 1
Less than Diploma 1.37 (0.53–3.51) 0.24 (0.04–1.27) 0.29 (0.05–1.55)
Illiterate 1.38 (0.53–3.58) 0.18 (0.03–0.94) 0.2 (0.04–1.07)
Marital status
Married 1 1 1
Single 1.24 (0.9–1.71) 1. 12 (0.78–1.6) 1.05 (0.38–2.89)
History of previous imprisonment
No 1 1
Yes 0.9 (0.6–1.37) 3.26 (0.42–24.87)
History of sharing injection in lifetime
No 1 1 1
Yes 0.94 (0.67–1.31) 3.42 (1.28–9.12) 3.36 (1.25–9.02)
History of unsafe sex in lifetime
No 1 1 1
Yes 1.56 (1.11–2.2) 1.59 (1.1–2.3) 1.31 (0.45–3.83)
History of tattooing in lifetime
No 1 1 1
Yes 1.22 (0.88–1.69) 1.28 (0.84–1.72) 0.64 (0.23–1.74)
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in the general population. Achieving the goal of eliminat-
ing viral hepatitis in Iran by 2030, in particular HCV,
requires a national commitment, and fast adoption of
appropriate strategies and measures in this high-risk
group. Considering the increased efficacy of HCV treat-
ment in recent years, treating prisoners can be an effec-
tive intervention. The prevalence of HBV is among
prisoners is double that of the general population, and
prisoners should therefore be considered a high-risk
group for HBV in need of immunisation of non-vacci-
nated individuals and extended harm reduction pro-
grammes. Although prisons are a high-risk setting, they
can offer an opportunity for the control of diseases as
they allow easy access to patients and enable the imple-
mentation of appropriate interventions.
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